UroGen Pharma Ltd.

UroGen Pharma Ltd. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. UroGen Pharma Ltd. is not very popular among insiders. Tradey thinks it is not wise to invest in UroGen Pharma Ltd..

UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non...

News

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of...\n more…

UroGen Pharma to Present at Upcoming Investor Conferences

Guggenheim Begins Coverage on UroGen Pharma (NASDAQ:URGN)

Ticker Report Guggenheim assumed coverage on shares of UroGen Pharma (NASDAQ:URGN - Free Report) in a research note released on Thursday, MarketBeat Ratings reports. The firm issued a buy rating and a $40.00 price...\n more…

UroGen Pharma initiated with bullish view at Guggenheim

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

UroGen Pharma Ltd. (NASDAQ:URGN) to Post Q3 2024 Earnings of ($0.80) Per Share, HC Wainwright Forecasts

Ticker Report UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) - Analysts at HC Wainwright cut their Q3 2024 EPS estimates for UroGen Pharma in a note issued to investors on Wednesday, August 14th. HC Wainwright...\n more…

HC Wainwright Reiterates Buy Rating for UroGen Pharma (NASDAQ:URGN)

Ticker Report UroGen Pharma (NASDAQ:URGN - Get Free Report)s stock had its "buy" rating restated by equities researchers at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They...\n more…